Restoring KLF5 in esophageal squamous cell cancer cells activates the JNK pathway leading to apoptosis and reduced cell survival

Neoplasia (United States)

Volumn 15, Issue 5, 2013, Pages 472-480

  Tarapore, Rohinton S ^a   Yang, Yizeng ^a   Katz, Jonathan P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL) CHROMONE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTHRA [1, 9 CD] PYRAZOL 6 (2H) ONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APOPTOSIS SIGNAL REGULATING KINASE 1; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CELL SURFACE PROTEIN; DOXYCYCLINE; KRUPPEL LIKE FACTOR 5; LUCIFERASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; PROTEIN BAX; STRESS ACTIVATED PROTEIN KINASE; TE15 PROTEIN; TE7 PROTEIN; UNCLASSIFIED DRUG; BAX PROTEIN, HUMAN; KLF5 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MAP2K4 PROTEIN, HUMAN; MAP3K5 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DENSITOMETRY; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ANALYSIS; SQUAMOUS CELL CARCINOMA; UPREGULATION; WESTERN BLOTTING; ENZYME INDUCTION; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME INDUCTION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MAP KINASE KINASE 4; MAP KINASE KINASE KINASE 5; MAP KINASE SIGNALING SYSTEM; NEOPLASMS, SQUAMOUS CELL; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84877081879     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.122126     Document Type: Article

References (47)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D. (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
2. Enzinger PC and Mayer RJ (2003). Esophageal cancer. N Engl J Med 349, 2241-2252.
3. Jemal A, Center MM, DeSantis C, and Ward EM (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19, 1893-1907.
4. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al. (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366, 2074-2084.
5. Lin J and Beerm DG (2004). Molecular biology of upper gastrointestinal malignancies. Semin Oncol 31, 476-486.
6. McConnell BB, Ghaleb AM, Nandan MO, and Yang VW (2007). The diverse functions of Krüppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays 29, 549-557.
7. Goldstein BG, Chao HH, Yang Y, Yermolina YA, Tobias JW, and Katz JP (2007). Overexpression of Kruppel-like factor 5 in esophageal epithelia in vivo leads to increased proliferation in basal but not suprabasal cells. Am J Physiol Gastrointest Liver Physiol 292, G1784-G1792.
8. Yang Y, Goldstein BG, Nakagawa H, and Katz JP (2007). Krüppel-like factor 5 activates MEK/ERK signaling via EGFR in primary squamous epithelial cells. FASEB J 21, 543-550.
9. Yang Y, Nakagawa H, Tetreault MP, Billig J, Victor N, Goyal A, Sepulveda AR, and Katz JP (2011). Loss of transcription factor KLF5 in the context of p53 ablation drives invasive progression of human squamous cell cancer. Cancer Res 71, 6475-6484.
10. Yang Y, Tetreault MP, Yermolina YA, Goldstein BG, and Katz JP (2008). Krüppel-like factor 5 controls keratinocyte migration via the integrin-linked kinase. J Biol Chem 283, 18812-18820.
11. Yang Y, Goldstein BG, Chao HH, and Katz JP (2005). KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther 4, 1216-1221.
12. Yang Y, Tarapore RS, Jarmel MH, Tetreault MP, and Katz JP (2012). p53 mutation alters the effect of the esophageal tumor suppressor KLF5 on keratinocyte proliferation. Cell Cycle 11, 4033-4039.
13. Bateman NW, Tan D, Pestell RG, Black JD, and Black AR (2004). Intestinal tumor progression is associated with altered function of KLF5. J Biol Chem 279, 12093-12101.
14. Dotto GP (2008). Notch tumor suppressor function. Oncogene 27, 5115-5123.
15. Chen C, Bhalala HV, Qiao H, and Dong JT (2002). A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21, 6567-6572.
16. Chen C, Bhalala HV, Vessella RL, and Dong JT (2003). KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 55, 81-88.
17. Davis RJ (2000). Signal transduction by the JNK group of MAP kinases. Cell 103, 239-252.
18. Johnson GL and Lapadat R (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912.
19. Dhanasekaran DN and Reddy EP (2008). JNK signaling in apoptosis. Oncogene 27, 6245-6251.
20. Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, and Davis RJ (2001). MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 15, 1419-1426.
21. Haeusgen W, Herdegen T, and Waetzig V (2011). The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7. Eur J Cell Biol 90, 536-544.
22. Soga M, Matsuzawa A, and Ichijo H (2012). Oxidative stress-induced diseases via the ASK1 signaling pathway. Int J Cell Biol 2012, 439587.
23. Ventura JJ, Hubner A, Zhang C, Flavell RA, Shokat KM, and Davis RJ (2006). Chemical genetic analysis of the time course of signal transduction by JNK. Mol Cell 21, 701-710.
24. Wagner EF and Nebreda AR (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537-549.
25. Nishihira T, Hashimoto Y, Katayama M, Mori S, and Kuroki T (1993). Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 119, 441-449.
26. Boonstra JJ, van der Velden AW, Beerens EC, van Marion R, Morita-Fujimura Y, Matsui Y, Nishihira T, Tselepis C, Hainaut P, Lowe AW, et al. (2007). Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res 67, 7996-8001.
27. Dudley DT, Pang L, Decker SJ, Bridges AJ, and Saltiel AR (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92, 7686-7689.
28. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S, and Hong WK (2005). Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 11, 6065-6074.
29. Friedlander P, Haupt Y, Prives C, and Oren M (1996). A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16, 4961-4971.
30. Schug J (2008). Using TESS to predict transcription factor binding sites in DNA sequence. Curr Protoc Bioinformatics Chapter 2, Unit 2.6.
31. Soldani C and Scovassi AI (2002). Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7, 321-328.
32. Boatright KM and Salvesen GS (2003). Mechanisms of caspase activation. Curr Opin Cell Biol 15, 725-731.
33. Bogoyevitch MA and Arthur PG (2008). Inhibitors of c-Jun N-terminal kinases: JuNK no more? Biochim Biophys Acta 1784, 76-93.
34. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, et al. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98, 13681-13686.
35. Ghaleb AM, Nandan MO, Chanchevalap S, Dalton WB, Hisamuddin IM, and Yang VW (2005). Krüppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res 15, 92-96.
36. Sabapathy K (2012). Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci 106, 145-169.
37. Raman M, Chen W, and Cobb MH (2007). Differential regulation and properties of MAPKs. Oncogene 26, 3100-3112.
38. Kyriakis JM and Avruch J (2012). Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 92, 689-737.
39. Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
40. Dong JT and Chen C (2009). Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cell Mol Life Sci 66, 2691-2706.
41. Shen-Orr SS, Milo R, Mangan S, and Alon U (2002). Network motifs in the transcriptional regulation network of Escherichia coli. Nat Genet 31, 64-68.
42. Lindsay J, Esposti MD, and Gilmore AP (2011). Bcl-2 proteins and mitochondria-specificity in membrane targeting for death. Biochim Biophys Acta 1813, 532-539.
43. Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y, Yoshioka K, Masuyama N, and Gotoh Y (2004). JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23, 1889-1899.
44. Nomura M, Shimizu S, Sugiyama T, Narita M, Ito T, Matsuda H, and Tsujimoto Y (2003). 14-3-3 Interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 278, 2058-2065.
45. Liu J and Lin A (2005). Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15, 36-42.
46. Shaulian E and Karin M (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4, E131-E136.
47. Potapova O, Gorospe M, Dougherty RH, Dean NM, Gaarde WA, and Holbrook NJ (2000). Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner. Mol Cell Biol 20, 1713-1722.